Physician profile
Daniel Sherer
NPI 1477548261
$1,904.56
in general payments reported to CMS, 2019-2025
16 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $131 · 2021: $136 · 2022: $418 · 2023: $195 · 2024: $140 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.02 |
| Education | $175.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $398.52 | 2019-2025 | |
| Merz North America, INC. | $240.80 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $217.06 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $179.22 | 2019-2025 | Tremfya |
| Genzyme Corporation | $157.94 | 2020-2022 | |
| Abbvie INC. | $156.26 | 2021-2024 | Skyrizi |
| Leo Pharma INC. | $101.18 | 2022-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $97.09 | 2019-2022 | |
| Pfizer INC. | $93.15 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Incyte Corporation | $59.62 | 2022-2023 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.38 | 2019-2020 | |
| Amgen INC. | $25.96 | 2023 | Otezla |
| Almirall LLC | $24.44 | 2019 | |
| Verrica Pharmaceuticals INC. | $19.58 | 2024 | Ycanth |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $18.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sherer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.